These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35249409)

  • 21. Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
    Bausback Y; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
    J Endovasc Ther; 2017 Aug; 24(4):459-467. PubMed ID: 28558502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictability and usefulness of intravascular ultrasound-guided angioplasty in patients with femoropopliteal lesions.
    Jiang J; Xu W
    Int Angiol; 2022 Feb; 41(1):74-81. PubMed ID: 34825800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary Patency of Long-Segment Femoropopliteal Artery Lesions in Patients with Peripheral Arterial Occlusive Disease Treated with Paclitaxel-Eluting Technology.
    Phair J; Carnevale M; Lipsitz EC; Shariff S; Scher L; Garg K
    Ann Vasc Surg; 2020 Jul; 66():595-600. PubMed ID: 31863948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.
    Mori S; Hirano K; Nakano M; Muramatsu T; Tsukahara R; Ito Y; Ishimori H
    J Endovasc Ther; 2015 Jun; 22(3):341-9. PubMed ID: 25862363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in Intravascular Ultrasound Measurement Values Between Treatment Modalities for Restenosis in Femoropopliteal Lesions.
    Aihara H; Higashitani M; Takimura H; Tobita K; Jujo K; Hozawa K; Yamaguchi T; Iwata Y; Tokuyama H; Sakurai M; Murata N; Fujimoto Y; Kikuchi A; Koganei H; Sato A; Noguchi Y; Ieda M
    Circ J; 2020 Jul; 84(8):1320-1329. PubMed ID: 32581151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Laser Atherectomy Combined With Drug-Coated Balloon Angioplasty Is Associated With Improved 1-Year Outcomes for Treatment of Femoropopliteal In-Stent Restenosis.
    Kokkinidis DG; Hossain P; Jawaid O; Alvandi B; Foley TR; Singh GD; Waldo SW; Laird JR; Armstrong EJ
    J Endovasc Ther; 2018 Feb; 25(1):81-88. PubMed ID: 29219030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort.
    Brodmann M; Keirse K; Scheinert D; Spak L; Jaff MR; Schmahl R; Li P; Zeller T;
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2113-2123. PubMed ID: 29050631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcome of drug-coated balloon versus scaffold device in patients with superficial femoral artery chronic total occlusion.
    Hayakawa N; Kodera S; Arakawa M; Hirano S; Shakya S; Kanda J
    Heart Vessels; 2022 Feb; 37(2):282-290. PubMed ID: 34279711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions.
    Laird JA; Schneider PA; Jaff MR; Brodmann M; Zeller T; Metzger DC; Krishnan P; Scheinert D; Micari A; Wang H; Masters M; Tepe G
    Circ Cardiovasc Interv; 2019 Jun; 12(6):e007702. PubMed ID: 31195825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of non-flow-limiting spiral dissection after drug-coated balloon angioplasty for de novo femoropopliteal lesions.
    Haraguchi T; Kuramitsu S; Tsujimoto M; Kashima Y; Sato K; Fujita T
    Catheter Cardiovasc Interv; 2024 Jan; 103(1):97-105. PubMed ID: 37975201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-Year Outcomes of Orbital Atherectomy Combined With Drug-Coated Balloon Angioplasty for Treatment of Heavily Calcified Femoropopliteal Lesions.
    Kokkinidis DG; Jawaid O; Cantu D; Martinsen BJ; Igyarto Z; Valle JA; Waldo SW; Armstrong EJ
    J Endovasc Ther; 2020 Jun; 27(3):492-501. PubMed ID: 32364000
    [No Abstract]   [Full Text] [Related]  

  • 32. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
    Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
    J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease.
    Herten M; Torsello GB; Schönefeld E; Stahlhoff S
    Vasc Health Risk Manag; 2016; 12():341-56. PubMed ID: 27621646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lumen Gain After Endovascular Therapy in Calcified Superficial Femoral Artery Occlusive Disease Assessed by Intravascular Ultrasound (CODE Study).
    Fujihara M; Kozuki A; Tsubakimoto Y; Takahara M; Shintani Y; Fukunaga M; Iwasaki Y; Nakama T; Yokoi Y
    J Endovasc Ther; 2019 Jun; 26(3):322-330. PubMed ID: 30873909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons Versus Standard Percutaneous Transluminal Angioplasty: Results From the IN.PACT SFA II Trial.
    Salisbury AC; Li H; Vilain KR; Jaff MR; Schneider PA; Laird JR; Cohen DJ
    JACC Cardiovasc Interv; 2016 Nov; 9(22):2343-2352. PubMed ID: 27884360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
    Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
    JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Outcomes of the 150 mm Drug-Coated Balloon Cohort from the IN.PACT Global Study.
    Brodmann M; Lansink W; Guetl K; Micari A; Menk J; Zeller T
    Cardiovasc Intervent Radiol; 2022 Sep; 45(9):1276-1287. PubMed ID: 35864209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk Factors for Restenosis after Drug-coated Balloon Angioplasty for Complex Femoropopliteal Arterial Occlusive Disease.
    Roh JW; Ko YG; Ahn CM; Hong SJ; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Jang Y
    Ann Vasc Surg; 2019 Feb; 55():45-54. PubMed ID: 30118857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-coated balloon versus plain old balloon angioplasty in femoropopliteal disease: An updated meta-analysis of randomized controlled trials.
    Anantha-Narayanan M; Shah SM; Jelani QU; Garcia S; Ionescu C; Regan C; Mena-Hurtado C
    Catheter Cardiovasc Interv; 2019 Jul; 94(1):139-148. PubMed ID: 30838719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Rotational Atherectomy Followed by Drug-coated Balloon Angioplasty for the Treatment of Femoropopliteal Lesions-Comparison with Sole Drug-coated Balloon Revascularization: Two-year Outcomes.
    Rodoplu O; Oztas DM; Meric M; Beyaz MO; Ulukan MO; Yildiz CE; Unal O; Ugurlucan M
    Ann Vasc Surg; 2021 May; 73():222-233. PubMed ID: 33359329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.